Sol-Gel Technologies Ltd. Ordinary Shares (SLGL) Stock Price

SLGLStock

$81.72+241.38%52W

Market Cap$267.14M

P/E—

PEG Ratio—

Div yield—

Beta1.20

SLGL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-15.71%

Price vs S&P 500 (4W)-9.89%

VGM Score47.77

P/CF (Annual)835.32x

Book Value / Share (Quarterly)$15.73

P/TBV (Annual)0.92x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)70.96%

Cash Flow / Share (Quarterly)$0.10

Price vs S&P 500 (YTD)71.69%

Net Profit Margin (TTM)-5.66%

EPS (TTM)$-0.35

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-0.35

Revenue Growth (5Y)17.19%

EPS (Annual)$-2.20

ROI (Annual)-26.86%

Net Profit Margin (5Y Avg)-450.06%

Cash / Share (Quarterly)$16.16

Revenue Growth QoQ (YoY)-89.52%

ROA (Last FY)-20.48%

Revenue Growth TTM (YoY)52.57%

EBITD / Share (TTM)$2.85

ROE (5Y Avg)-32.71%

Operating Margin (TTM)-12.59%

Cash Flow / Share (Annual)$0.10

P/B Ratio5.23x

P/B Ratio (Quarterly)5.00x

Net Income / Employee (Annual)$-218,800

EV / Revenue (TTM)14.02x

Net Interest Coverage (TTM)-1037.50x

ROA (TTM)-2.58%

EV / EBITDA (TTM)32.65x

EPS Incl Extra (Annual)$-2.20

Current Ratio (Annual)4.37x

Quick Ratio (Quarterly)8.54x

3-Month Avg Trading Volume0.04M

52-Week Price Return241.38%

EV / Free Cash Flow (Annual)941.22x

Revenue / Employee (TTM)$659,500

Tangible BV / Share (Quarterly)$1.74

P/S Ratio (Annual)13.87x

Asset Turnover (Annual)0.65x

52-Week High$97.97

Operating Margin (5Y Avg)-487.58%

EPS Excl Extra (Annual)$-2.20

CapEx CAGR (5Y)-36.35%

26-Week Price Return-4.47%

Quick Ratio (Annual)4.21x

13-Week Price Return13.29%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.84x

Enterprise Value$258.84M

Revenue / Share Growth (5Y)78.08%

Asset Turnover (TTM)0.45x

Book Value / Share Growth (5Y)26.85%

Revenue / Employee (Annual)$692,400

Pretax Margin (Annual)-31.60%

Cash / Share (Annual)$8.61

3-Month Return Std Dev72.02%

Net Income / Employee (TTM)$-37,400

ROE (Last FY)-26.86%

EPS Basic Excl Extra (Annual)$-2.20

Receivables Turnover (TTM)7.46x

EV / Free Cash Flow (TTM)941.22x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.35

Receivables Turnover (Annual)6.97x

ROI (TTM)-3.17%

P/S Ratio (TTM)14.57x

Pretax Margin (5Y Avg)-450.06%

Revenue / Share (Annual)$6.96

Tangible BV / Share (Annual)$1.83

Price vs S&P 500 (52W)223.07%

Year-to-Date Return83.65%

5-Day Price Return-2.45%

EPS Normalized (Annual)$-2.20

ROA (5Y Avg)-27.50%

Net Profit Margin (Annual)-31.60%

Month-to-Date Return-5.91%

EBITD / Share (Annual)$-2.67

Operating Margin (Annual)-38.88%

P/CF (TTM)835.32x

ROI (5Y Avg)-32.71%

EPS Basic Excl Extra (TTM)$-0.35

P/TBV (Quarterly)0.80x

P/B Ratio (Annual)5.15x

Pretax Margin (TTM)-5.66%

Book Value / Share (Annual)$8.19

Price vs S&P 500 (13W)10.50%

Beta1.20x

P/FCF (Annual)978.08x

Revenue / Share (TTM)$6.51

ROE (TTM)-3.17%

52-Week Low$20.06

vGradeD

gGradeC

mGradeB

vgmGradeC

SLGL Earnings Surprise History

Q2 254.17est. —

Q3 25-2.13est. -2.09

Q4 25-1.06est. 0.39

Q1 26-1.31est. -2.86

Q2 26-1.13est. -2.31

SLGL Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

4.13

4.10

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
SLGLSol-Gel Technologies Ltd. Ordinary Shares	D	C	B	$81.72
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Sol-Gel Technologies Ltd. Ordinary Shares

Sol-Gel Technologies develops branded and generic topical pharmaceuticals for dermatology, with a focus on rare skin diseases. Its lead asset, SGT-610 (Patidegib Gel 2%), is a hedgehog pathway blocker targeting basal cell carcinoma prevention in Gorlin syndrome. The company also develops SGT-210 for rare keratosis-related indications such as Darier Disease, PC, PPK, and Olmsted.